Sermorelin and ipamorelin get compared constantly, usually as though they are two versions of the same thing. They are not. They belong to two different pharmacological classes that happen to act on the same endocrine axis from opposite directions.
Sermorelin is a growth hormone releasing hormone (GHRH) analog. Ipamorelin is a selective ghrelin receptor agonist, a class usually called growth hormone secretagogues. One binds the GHRH receptor. The other binds GHS-R1a. Both signal to the same population of cells in the anterior pituitary, through different receptors and different intracellular pathways.
That distinction is the entire post. It explains the mechanism differences, it explains why the two classes are frequently examined together rather than against each other, and it explains why the CJC-1295 and ipamorelin combination exists as a studied pairing rather than as a marketing invention.
Everything below describes published pharmacology. All compounds referenced are supplied for laboratory and research use only and are not for human consumption. Nothing here is dosing guidance, administration guidance, or safety guidance.
The short version
| Sermorelina | Ipamorelin | |
|---|---|---|
| Clase | GHRH analog | Ghrelin receptor agonist (GH secretagogue) |
| Sequence | GRF(1-29) amide, 29 amino acids | Aib-His-D-2-Nal-D-Phe-Lys-NH2, 5 amino acids |
| Receptor target | GHRH receptor (GHRHR) | Growth hormone secretagogue receptor 1a (GHS-R1a) |
| Endogenous ligand it mimics | GHRH | Ghrelin |
| First characterized | 1980s, as the active fragment of GHRH | 1998, Raun et al. |
| Reported plasma stability | Short, cleared in minutes | Reported elimination half-life around 2 hours, several times longer than the GHRH analogs |
| Commonly paired with | Ghrelin mimetics in research combinations | GHRH analogs such as CJC-1295 without DAC |
What sermorelin is
Native human GHRH is a 44-amino-acid hypothalamic peptide. Early structure-activity work established that biological activity resides almost entirely in the first 29 residues, and that the shorter fragment retains the full potency of the parent molecule at the GHRH receptor. Sermorelin is the synthetic version of that fragment: GRF(1-29) amide.
The receptor it binds, GHRHR, is a class B G protein coupled receptor expressed on somatotroph cells in the anterior pituitary. Binding activates Gs, raises intracellular cAMP, and drives protein kinase A signalling. Downstream of that, the somatotroph both synthesizes and releases growth hormone.
Two properties of that pathway show up repeatedly in the literature and matter for how sermorelin is used as a research tool:
- It works upstream of the pituitary output, not in place of it. Sermorelin prompts release of endogenously produced growth hormone rather than supplying an exogenous hormone. That means the somatostatin brake and the IGF-1 negative feedback loop stay in the circuit. Investigators studying feedback regulation rely on this.
- It is cleared quickly. GHRH and its short fragments carry a dipeptidyl peptidase-4 cleavage site at the N-terminus. Published pharmacokinetic work reports a plasma half-life measured in minutes. That short window is the specific problem the later GHRH analogs were engineered to solve, which is covered in tesamorelin vs sermorelin.
Sermorelin acetate held a pharmaceutical marketing authorization in the United States under the brand name Geref, used as a diagnostic agent for pituitary function and in pediatric endocrinology. Its marketing was discontinued in 2008, and FDA formally withdrew the approval in 2009. That was a commercial and supply decision by the marketing authorization holder, not a regulatory withdrawal. The compound continued as a research reference standard, which is the form sermorelin is supplied as today.
What ipamorelin is
Ipamorelin is a pentapeptide, five residues, several of them unnatural amino acids. It descends from the growth hormone secretagogue lineage that produced GHRP-6 and GHRP-2, developed at Novo Nordisk, and it was described in 1998 by Raun and colleagues in a paper whose title states the point directly: the first selective growth hormone secretagogue.
It binds GHS-R1a, the receptor for ghrelin. GHS-R1a is a class A GPCR, Gq coupled, and signals through phospholipase C, IP3, and intracellular calcium release. That is a different receptor, a different G protein, and a different second messenger system than the GHRH pathway.
Published characterization of ipamorelin reports two mechanistic points that account for most of the research interest in it:
- Selectivity within the secretagogue class. The original characterization compared ipamorelin against GHRP-6 and reported growth hormone release of comparable potency, but without the concurrent increases in ACTH and cortisol that the earlier secretagogues produced in the same models. This is the finding people are actually referring to when they ask which compound is “safer.” It is a receptor selectivity result reported in animal and in vitro models, not a human safety conclusion.
- The receptor class it works through is also reported to reduce somatostatin tone. Ghrelin receptor agonists as a class act partly through hypothalamic circuits, including release of the somatostatin brake, which is a different lever than direct GHRH receptor stimulation. That is a class-level property of the receptor system rather than a finding specific to the 1998 characterization.
Ipamorelin is supplied as a research compound in 5mg and 10mg vial sizes.
Mechanism comparison
| Property | Sermorelina | Ipamorelin |
|---|---|---|
| Receptor | GHRHR | GHS-R1a |
| Receptor family | Class B GPCR | Class A GPCR |
| G protein coupling | Gs | Gq |
| Second messenger | cAMP, PKA | PLC, IP3, intracellular calcium |
| Primary reported action at the pituitary | Direct stimulation of somatotroph GH synthesis and release | Stimulation of GH release plus reduction of somatostatin tone |
| Endogenous feedback preserved | Yes, somatostatin and IGF-1 loops remain in circuit | Yes |
| Reported cross-axis activity | GHRH pathway is axis-specific | Selectivity reported vs ACTH and cortisol in the original characterization |
| Structural size | 29 residues | 5 residues |
| Clase molecular | Peptide hormone fragment | Small synthetic peptide, unnatural residues |
Why research protocols pair the two classes
If two compounds act on the same axis through separate receptors, the interesting experiment is not which one wins. It is what happens when both are present.
That question has been asked in endocrinology since well before either of these specific molecules existed. Studies combining a GHRH analog with a ghrelin receptor agonist consistently report a larger growth hormone response than either class produced alone in the same model. The two inputs are plainly not redundant - one drives the somatotroph directly through cAMP while the other works through the ghrelin receptor system - but the mechanism behind the outsized combined response has never been fully resolved. The foundational work on the combination specifically found that somatostatin withdrawal alone did not explain it, and reviews still describe the responsible factor as unidentified. The synergy is one of the better-replicated observations in this literature; the explanation for it is not.
This is the entire reason combination research designs exist in this space, and it is why a GHRH analog paired with a ghrelin mimetic is one of the most examined configurations on the growth hormone axis.
Why CJC-1295 is the GHRH analog usually paired with ipamorelin
Search volume for “cjc-1295 ipamorelin” runs several times higher than for either compound on its own, which tells you the pairing is what people are actually researching.
The reason CJC-1295 without DAC, rather than sermorelin, ended up as the standard GHRH-side partner is stability. CJC-1295 without DAC is often written as mod GRF(1-29). It is the same 29-residue GHRH fragment as sermorelin with four amino acid substitutions, D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27. The substitution at position 2 is the important one: it sits directly on the dipeptidyl peptidase-4 cleavage site that limits how long unmodified GRF(1-29) survives in plasma. Blocking that site is the headline engineering objective; the other three substitutions address deamidation and oxidation liabilities.
The result is a GHRH analog with the same receptor target as sermorelin and a longer reported stability profile, which makes it a more practical partner in a two-compound research design. That is why CJC-1295 no DAC with ipamorelin exists as a single pack rather than as two separate line items.
One naming note worth having straight: in the published literature, CJC-1295 properly refers to the DAC-bearing compound - “without DAC” is market shorthand for what the literature calls Modified GRF(1-29). The DAC version is a different molecule again. Drug Affinity Complex is a maleimide group that bonds covalently to serum albumin and extends circulating time from minutes to days. That changes the shape of the growth hormone signal from a pulse to a sustained elevation, which is a meaningfully different experimental condition. Research designs that are specifically interested in preserving pulsatility use the no-DAC version.
What each compound is examined for
Neither compound has an approved human indication in the form sold as a research chemical, and nothing below is a claim about outcomes.
Sermorelin appears in published research examining:
- GHRH receptor binding kinetics and structure-activity relationships across GHRH fragments
- Pituitary somatotroph responsiveness as a marker of pituitary function
- Hypothalamic-pituitary axis feedback regulation, using an intact endogenous release model
- Age-related changes in growth hormone axis output in animal models
- Comparative pharmacology against longer-acting GHRH analogs
Ipamorelin appears in published research examining:
- GHS-R1a receptor selectivity and the pharmacology that separates it from earlier secretagogues
- Somatostatin tone and its role in modulating pituitary output
- Gastrointestinal motility, an independent line of ghrelin receptor research separate from the growth hormone axis
- Bone density and body composition endpoints in animal models
- Combination pharmacology with GHRH analogs
Practical differences when sourcing either compound
For a lab or a reseller, the mechanism distinction has a few downstream consequences worth knowing.
Peptide length affects synthesis cost and impurity profile. A 29-residue peptide has more synthesis steps and more opportunities for deletion sequences than a 5-residue peptide. That is part of why sermorelin carries a higher per-vial cost than ipamorelin at the same milligram strength, and part of why the purity spec on the certificate of analysis matters more on longer sequences.
Both are supplied as lyophilized powder in 10-vial packs. Storage is standard cold chain for lyophilized peptides. Handling and solvent parameters are documented in the published peptide chemistry literature and are the researcher’s call, not ours to specify.
Check the COA before you check the price. Every batch we ship has one. You can browse the COA library without an account. Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.
Common questions
What is the difference between sermorelin and ipamorelin?
They act on different receptors. Sermorelin is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs and signals through cAMP. Ipamorelin is a ghrelin receptor agonist that binds GHS-R1a and signals through intracellular calcium while also reducing somatostatin tone. Both converge on growth hormone release from the same cell population, but they arrive there by separate routes.
Sermorelin vs ipamorelin: what does the literature report about receptor selectivity?
This question is usually asked as which compound is “safer.” That is a clinical question and we do not answer it. What the published literature reports is a selectivity finding: the 1998 characterization of ipamorelin compared it against GHRP-6 and found growth hormone release of comparable potency without the concurrent ACTH and cortisol elevation the earlier secretagogue produced in the same models. Sermorelin, acting at the GHRH receptor, is likewise reported as axis-specific. Those are pharmacological observations in research models. They are not safety conclusions about human use, and neither compound is approved for human use in the form sold here.
Why is ipamorelin usually paired with CJC-1295 rather than sermorelin?
Stability. CJC-1295 without DAC is the same GHRH fragment as sermorelin with four substitutions, one of which blocks the dipeptidyl peptidase-4 cleavage site that clears unmodified GRF(1-29) within minutes. In a two-compound research design, the longer-lived GHRH analog is the more practical partner. The receptor target is identical.
Do sermorelin and ipamorelin compete for the same receptor?
No. They bind different receptors from different GPCR classes. That non-overlap is exactly why combination designs are studied. If they competed for one binding site, adding the second compound would displace the first rather than add to it.
Is ipamorelin a growth hormone?
No. Neither compound is growth hormone. Both act on cells that produce growth hormone endogenously. That distinction is the reason both classes are studied as tools for examining axis regulation, where exogenous recombinant growth hormone would override the feedback loops being measured.
What is CJC-1295 without DAC?
A GHRH analog, also written as mod GRF(1-29). It is the same 29-residue fragment as sermorelin carrying four amino acid substitutions that improve resistance to enzymatic cleavage. The DAC version adds an albumin-binding group that extends circulating time substantially and changes the release profile from pulsatile to sustained.
Where to source these compounds
We manufacture both compounds and ship direct, in 10-vial packs, with no retail packaging in between. That is why the vials arrive unlabeled and why the per-vial cost is what it is.
- Sermorelin, 5mg
- Ipamorelin, 5mg and 10mg
- CJC-1295 no DAC with ipamorelin, 5mg/5mg blend
If you are comparing GHRH analogs against each other rather than across classes, the companion piece is tesamorelin vs sermorelin.
All products are supplied for laboratory and research use only. Not for human consumption, ingestion, injection, or therapeutic use.